FDA proposed keeping three GLP‑1 ingredients off the 503B bulks list

On April 30, 2026, the Food and Drug Administration proposed that semaglutide, tirzepatide, and liraglutide not be included on the agency's 503B bulks list. The Federal Register notice was published May 1. Although the original headline described removal, the more precise description is that FDA proposed not adding the three nominated ingredients to the list.

Section 503B applies to registered outsourcing facilities. It allows those facilities to compound certain medicines under federal conditions, including some exemptions from the standard drug-approval requirements. In most circumstances, an outsourcing facility may compound from a bulk drug substance only when that ingredient appears on the 503B bulks list or when the finished drug is on FDA's shortage list at the relevant time.

FDA said it reviewed the nominations and did not find enough evidence of a clinical need for outsourcing facilities to make these medicines from bulk substances. Its assessment considered patient safety and medical necessity under the statute. The agency invited comments before reaching a final decision.

The notice addressed a specific federal pathway. Traditional pharmacies and physicians that compound under section 503A operate under a different set of conditions, including requirements tied to prescriptions for identified patients. Other federal and state rules can also affect whether a particular preparation is lawful.

On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that outsourcing facilities may use for compounding under section 503B. The agency requested public comment; a proposal is not a final rule. The notice concerns the conditions under which registered outsourcing facilities may compound from bulk substances. It does not by itself resolve whether a specific compounded product or patient prescription is lawful.

The proposal narrows one federal compounding pathway

The proposal would keep large outsourcing facilities from relying on 503B bulks-list status for these three active ingredients. It also shows that the end of a drug shortage and the separate clinical-need review can each matter when an outsourcing facility decides whether it may compound a medicine from bulk material.

Patients can ask who made a compounded product, whether the facility is registered with FDA as an outsourcing facility, which compounding pathway it uses, and why the prescriber believes a compounded preparation is needed. FDA approval, compounding under 503A, and compounding under 503B are different legal and regulatory categories.

The proposal signals tighter federal scrutiny of large-scale compounding from bulk GLP-1 ingredients. Patients using a compounded product can ask the prescriber and dispensing pharmacy which legal pathway applies and whether an FDA-approved product is suitable.

The proposal is not a final order

The April action was a proposal, not a final order. It did not itself declare every existing prescription unlawful, recall a named product, or decide whether one patient's preparation met all applicable requirements. It also did not cover every question about copies of commercially available medicines or shortage-related enforcement policy.

A finding that FDA had not identified a clinical need for 503B bulk compounding is not a head-to-head safety trial. It does not establish that every compounded product caused harm, and it does not tell an individual patient to stop treatment. Compounded medicines do not undergo the same premarket review as FDA-approved products, so product source and clinical rationale still matter.

The proposal does not prove a particular compounded product is unsafe, predict supply or price changes, or direct patients to switch products. It is not final agency action and should not be treated as individualized medical or legal advice.